Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

NCT07800871 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT07800871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07800871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases
Lead sponsor
Fate Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
October 31, 2040
Enrollment
446 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis (aav), idiopathic inflammatory myositis (iim), rheumatoid arthritis (ra), systemic lupus erythematosus (sle), systemic sclerosis (ssc)